Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran Etexilate for VTE Prevention After Hip Replacement (RE-NOVATE)
NCT00168818Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2004
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in venous thromboembolism (VTE) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period. Started Nov 2004; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00168818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168818.